Project Grant K23HL172699

This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $422,894 to support research examining the interactive effects of cardiorespiratory fitness and adiposity on the recovery of impaired glucose and vascular control following a period of physical inactivity. The award period is from April 20, 2025 to March 31, 2028. The key objectives of the project are to: 1) investigate how existing health status...

This $442,590 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a randomized controlled trial examining the effects of low-volume sprint interval training on cardiorespiratory fitness. The project, led by California State University San Marcos Corp, aims to provide evidence on the potential for this time-efficient exercise approach to improve fitness and address the significant public health issue of physical inactivity. The grant period runs...

The federal Project Grant award, titled "Adding Inspiratory Muscle Training to Optimize Cardiac Rehabilitation for Heart Failure," is funded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research). The $745,851 grant, awarded on September 1, 2025, supports research aimed at improving exercise tolerance and reducing exertional symptoms in patients with heart failure with reduced ejection fraction (HFrEF). The key objectives are to: 1) test if...

This $798,698 project grant, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to comprehensively characterize cardiac and physical function in youth with perinatally-acquired HIV (YPNHIV) compared to HIV-unexposed (HU) and HIV-exposed uninfected (PHEU) individuals. The research will utilize cardiac imaging, physical function assessment, autonomic dysfunction analysis, and molecular profiling to elucidate determinants of...

The National Heart Lung and Blood Institute (NHLBI) awarded a $3,264,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to study the mechanisms underlying the increased risk of sudden cardiac death in people with HIV. The research aims to characterize the myocardial tissue effects of treated HIV, including immune activation, cardiac ion channel dysregulation, and region-specific arrhythmic...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $249,000.00 to The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the oxygen cost of breathing and its impact on dyspnea and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF). The award aims to understand how obesity-related mechanical ventilatory constraints...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program for Cardiovascular Diseases Research (CFDA 93.837), provides $123,104 to Emory University to conduct research on factors contributing to cardiovascular disease (CVD) comorbidities in persons living with HIV (PWH). The key objectives are to: 1) assess relationships between the metabolome, lipidome, HIV reservoir, and subclinical CVD, analyzing differences by sex; and 2) determine...

This federal Project Grant award of $115,125.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the interaction between obstructive sleep apnea (OSA) and HIV infection on ventricular repolarization abnormalities. The research will be conducted by the University of Miami from February 1, 2025 to January 31, 2027. The goal is to delineate the independent and interactive effects of OSA and HIV on QT variability...

This federal Project Grant award of $2,981,544.00, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a study to assess the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with treated HIV infection. The study will leverage data from a prior clinical trial of the CMV-specific antiviral drug letermovir and a case-cohort study of over 1,900 ART-suppressed people with HIV to...

This Project Grant award, funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a feasibility study to assess the use of arteriovenous sampling to evaluate metabolic changes in the heart and legs during exercise in patients with heart failure with reduced ejection fraction. The $242,250 grant, awarded on September 1, 2025, will enable Duke University researchers to leverage interventional cardiologists and...